Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine (NASDAQ: EDIT), a gene editing company, has announced its participation in three major healthcare investor conferences in September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Editas Medicine (NASDAQ: EDIT), a gene editing company, has announced its participation in three major healthcare investor conferences in September 2025. The company will attend the Wells Fargo Healthcare Conference on September 3 in Boston, the Cantor Global Healthcare Conference on September 4 in New York featuring a fireside chat at 11:30 a.m. ET, and the Baird Global Healthcare Conference on September 9 in New York.
Live webcasts of available presentations can be accessed through the Investors section of Editas Medicine's website, with replays available for approximately 30 days after each event.
[]Details
News Market Reaction – EDIT
On Aug 27, the day this news came out, EDIT closed 2.20% below the previous close.
Data tracked by StockTitan Argus for the Aug 27 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September:
- Wells Fargo Healthcare Conference
Format: One-on-one Meetings
Date: Wednesday, September 3
Location: Boston, MA
- Cantor Global Healthcare Conference
Format: Fireside Chat with Webcast and One-on-one Meetings
Date: Thursday, September 4
Time: 11:30 a.m. ET
Location: New York, NY
- Baird Global Healthcare Conference.
Format: Presentation and One-on-one Meetings
Date: Tuesday, September 9
Location: New York, NY
To access the live webcasts (where available) of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Investor and Media Contacts: ir@editasmed.com media@editasmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.